Influence of choleretic therapy on the microRNA-4714-3p expression level in children with functional disorders of the gallbladder and Оddi's sphincter.
DOI:
https://doi.org/10.26641/2307-0404.2019.4.189196Ключевые слова:
functional disorders of the gallbladder and Oddi's sphincter, miRNA-4714-3p expression level, choleretic therapy, ursodeoxycholic acid, childrenАннотация
The high prevalence and possibility of transformation of functional disorders into organic pathology determine the relevance of the study of the cluster of functional disorders of the gallbladder and Oddi's sphincter (FD GB and OS) in children. Studies on the properties of ursodeoxycholic acid (UDCA) to alter the activity of generation of some microRNAs in various diseases of the hepatobiliary system have become important in view of the evidential impact on this process. The alm: to determine the effect of choleretic therapy with UDCA drugs addition on the microRNA-4714-3p expression level in functional disorders of the gallbladder and Oddi's sphincter in children. 70 children with FD GB and OS aged 4 to 14 years were examined. Main group included 50 children. They received standard therapy with UDCA combination. The comparison group included 20 patients receiving standard therapy without UDCA. A molecular genetic study was conducted to determine the microRNA-4714-3p expression level in serum before and after treatment by real-time polymerase chain reaction with reverse transcription according to TaqMan Gene Expression Assays. The correlation was established between the main anamnestic data, causative factors of development, clinical and paraclinical parameters of the FD GB and OS and the microRNA-4714-3p expression level in blood serum of children before therapy. The positive relationship of the microRNA-4714-3p expression profile with decrease in gallbladder contractility was determined (r=+0.36; p<0.05). It has been determined that in children with FD GB and OS after the combined therapy with UDCA, the mean value of the microRNA-4714-3p expression level in serum is significantly lower than before therapy (1.93±0.58 SU and 5.56±1.50 SU, respectively). A positive correlation was found between the microRNA-4714-3p expression level and the alkaline phosphatase activity level in the blood of children with FD GB and OS after therapy with UDCA addition (r=+0.33; p<0.05). There was no correlation between the microRNA-4714-3p expression level and the anamnestic, clinical-paraclinical parameters in children with FD GB and OS after treatment without UDCA. The effect of UDCA on the treatment of functional disorders of the gallbladder and Oddi's sphincter in children results in a decrease in the microRNA-4714-3p expression profile and is accompanied by the emergence of a direct correlation between low level of a microRNA-4714-3p expression and reduced alkaline phosphatase activity in serum.
Библиографические ссылки
Abaturov OE, Babich VL. [The role of microRNA in diseases of the biliary system]. Child's Health. 2017;7(12):155-61. Ukrainian. doi: https://doi.org/10.22141/2224-0551.12.7.2017.116191
Abaturov OE, Babich VL. [Drug modulation of activity of microRNA generation in functional disorders of the gallbladder and Oddi's sphincter in children]. Child's Health. 2019;2(14):53-59. Ukrainian. doi: https://doi.org/10.22141/2224-0551.14.2.2019.165544
Babich VL. [Application of ursodeoxycholic acid in the treatment of functional disorders of the biliary system]. Modern medical technology. 2017;3(34):64-70. Ukrainian.
Maydannik VG. [Roman Criteria IV (2016): What's New? ] International Journal of Pediatrics, Obstetrics and Gynecology. July/August 2016;1(10):8-18. Ukrainian.
Volosoveс OP, Zubarenko OV, Kryvopustov SP et al. [Pediatrics (Gastroenterology and Pathology of the Early Age): Teach. Manual]. Odessa: Printing house, Printing South. 2017:165-180. Ukrainian.
Unified clinical protocol of medical aid for children with diseases of the digestive system: Order of the Ministry of Health of Ukraine N 59 dated January 29, 2013. Modern Pediatrics. 2013;4:20-31. Ukrainian.
Pearson T, Caporaso JG, Yellowhair M, Martinez JA et al. Abstract A18: Gut microbiota changes in response to treatment with ursodeoxycholic acid (UDCA). Cancer research. 2017;CRC16-A18. doi: https://doi.org/10.1158/1538-7445.crc16-a18
Puik JR, Meijer LL, Le Large TY, Heger M, Dijk F, Funel N, Garajová I, Giovannetti E, Kazemier G. Circulating biliary tract microRNA signature discriminates cholangiocarcinoma from pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018, Chicago, IL. Philadelphia (PA): AACR; Cancer Res. 2018;78(13 Suppl):Abstract nr 493. doi: https://doi.org/10.1158/1538-7445.AM2018-493
Letelier P, Riquelme I, Hernández AH, Guzmán N, Farías JG, Roa JC. Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers. Int J Mol Sci. 2016;17(5):791. doi: https://doi.org/10.1158/1538-7445.crc16-a18
Hayes CN, Chayama K. MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma. Int. J. Mol. Sci. 2016 Feb;17(3):280. doi: https://doi.org/10.3390/ijms17030280
Sakamoto T, Morishita A, Nomura T, Tani J, Miyoshi H, et al. Identification of microRNA profiles associated with refractory primary biliary cirrhosis. Mol. Med. Rep. 2016 Oct;14(4):3350-6. doi: https://doi.org/10.1158/1538-7445.crc16-a18
Otsuka M, Kishikawa T, Yoshikawa T, et al. MicroRNAs and liver disease. J Hum Genet. 2016 May 26. doi: https://doi.org/10.1038/jhg.2016.53
Panella M, Carotenuto P, Braconi C. MicroRNAs link inflammation and primary biliary cholangitis. Non-coding RNA Investig. 2018;2:29. doi:https://doi.org/10.21037/ncri.2018.05.02
Tabibian JH, Lindor KD. Ursodeoxycholic Acid Treatment in Primary Sclerosing Cholangitis. Primary Sclerosing Cholangitis. 2017. doi: https://doi.org/10.1007/978-3-319-40908-5_11
Загрузки
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2019 Medicni perspektivi (Medical perspectives)
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
